- Home
- KLRS vs DXR Comparison
KLRS vs DXR Comparison
Compare KLRS & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- DXR
- Stock Information
- Founded
- KLRS 2019
- DXR 1970
- Country
- KLRS United States
- DXR United States
- Employees
- KLRS N/A
- DXR N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- DXR Medical/Dental Instruments
- Sector
- KLRS Health Care
- DXR Health Care
- Exchange
- KLRS Nasdaq
- DXR Nasdaq
- Market Cap
- KLRS 46.0M
- DXR 46.9M
- IPO Year
- KLRS N/A
- DXR N/A
- Fundamental
- Price
- KLRS $2.56
- DXR $10.85
- Analyst Decision
- KLRS Buy
- DXR Strong Buy
- Analyst Count
- KLRS 1
- DXR 1
- Target Price
- KLRS N/A
- DXR $25.00
- AVG Volume (30 Days)
- KLRS 45.1K
- DXR 80.2K
- Earning Date
- KLRS 08-13-2025
- DXR 01-01-0001
- Dividend Yield
- KLRS N/A
- DXR N/A
- EPS Growth
- KLRS N/A
- DXR 86.16
- EPS
- KLRS N/A
- DXR 0.11
- Revenue
- KLRS N/A
- DXR $119,714.00
- Revenue This Year
- KLRS N/A
- DXR N/A
- Revenue Next Year
- KLRS N/A
- DXR N/A
- P/E Ratio
- KLRS N/A
- DXR $99.82
- Revenue Growth
- KLRS N/A
- DXR N/A
- 52 Week Low
- KLRS $2.14
- DXR $6.55
- 52 Week High
- KLRS $24.15
- DXR $11.38
- Technical
- Relative Strength Index (RSI)
- KLRS 49.38
- DXR 57.35
- Support Level
- KLRS $2.37
- DXR $10.01
- Resistance Level
- KLRS $2.58
- DXR $11.02
- Average True Range (ATR)
- KLRS 0.18
- DXR 0.70
- MACD
- KLRS 0.01
- DXR 0.01
- Stochastic Oscillator
- KLRS 64.32
- DXR 71.35
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.